BioSpaceOriginal article
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
Phase 3MixedMerck experimental eye drugLucentisNegative
AI Analysis
Summary
Merck's experimental eye drug demonstrated efficacy comparable to Roche's approved Lucentis in late-stage trials but emerging safety concerns may impact its commercial prospects.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
efficacy matched Roche's Lucentis but safety concerns emerged
Importance:6/10
Sentiment:
-0.30
Phase 3ophthalmologysafety concernscompetitive comparisonVEGF inhibitor
Related Companies
Read the original article
Published by BioSpace on September 24, 2026 1:51 PM